GeneBioTech Co. ,Ltd (KOSDAQ:086060)

GeneBioTech Co. ,Ltd Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	10,301	10,279	8,751	7,430	7,430	8,794
Short-Term Investments	9,874	13,125	13,265	8,660	10,360	18,593
Cash & Short-Term Investments	20,175	23,404	22,016	16,090	17,790	27,387
Cash Growth	-13.67%	6.31%	36.83%	-9.56%	-35.04%	9.38%
Accounts Receivable	13,490	13,364	11,588	14,090	10,225	6,655
Other Receivables	412.19	356.36	180.69	183.82	74.85	80.37
Receivables	14,232	14,053	11,818	14,302	10,371	6,899
Inventory	17,523	17,041	14,802	15,452	13,676	10,441
Prepaid Expenses	21.76	27.27	24.16	25.66	41.05	44.35
Other Current Assets	1,552	1,310	621.38	399.76	298.05	698.85
Total Current Assets	53,504	55,836	49,281	46,269	42,175	45,470
Property, Plant & Equipment	16,839	13,924	14,159	14,615	14,900	12,910
Long-Term Investments	2,143	639.43	718.86	484.19	763.6	1,241
Goodwill	-	-	-	589.54	589.54	589.54
Other Intangible Assets	615.63	648.82	632.02	398.29	199.07	198.94
Long-Term Deferred Tax Assets	82.65	66.76	205.29	495.41	870.49	521.64
Other Long-Term Assets	294.27	436.81	513	666.71	294.23	376.97
Total Assets	73,895	71,988	66,017	64,041	60,368	62,085
Accounts Payable	3,290	3,366	3,540	3,901	4,752	1,671
Accrued Expenses	1,161	1,077	970.5	649.23	515.74	532.03
Short-Term Debt	8,386	10,851	7,704	9,486	8,042	4,352
Current Portion of Long-Term Debt	1,509	2,359	1,534	1,159	-	-
Current Portion of Leases	88.25	95.17	132.92	42.29	112.39	69.15
Current Income Taxes Payable	283.65	278.37	284.27	14.46	-	237.89
Current Unearned Revenue	-	-	-	-	-	1.96
Other Current Liabilities	350.27	337.78	347.33	667.94	716.5	815.97
Total Current Liabilities	15,068	18,364	14,513	15,920	14,139	7,680
Long-Term Debt	5,356	2,466	2,995	2,329	2,113	1,113
Long-Term Leases	101.87	113.47	135.08	12.35	33.57	68.66
Other Long-Term Liabilities	73.14	72.07	68.54	53.02	137	2,795
Total Liabilities	20,787	21,016	17,712	18,315	16,423	11,657
Common Stock	4,305	4,305	4,305	4,305	4,305	4,305
Additional Paid-In Capital	14,576	14,576	14,576	14,576	14,489	14,835
Retained Earnings	33,961	31,803	29,059	18,116	16,190	16,844
Comprehensive Income & Other	264.89	288.42	364.07	8,729	8,961	9,059
Total Common Equity	53,108	50,972	48,305	45,726	43,945	45,043
Shareholders' Equity	53,108	50,972	48,305	45,726	43,945	50,428
Total Liabilities & Equity	73,895	71,988	66,017	64,041	60,368	62,085
Total Debt	15,442	15,885	12,502	13,029	10,302	5,603
Net Cash (Debt)	4,734	7,519	9,514	3,061	7,488	21,784
Net Cash Growth	-36.56%	-20.97%	210.80%	-59.12%	-65.62%	182.38%
Net Cash Per Share	549.76	873.23	1104.91	355.50	869.68	2529.89
Filing Date Shares Outstanding	8.61	8.61	8.61	8.61	8.61	8.61
Total Common Shares Outstanding	8.61	8.61	8.61	8.61	8.61	8.61
Working Capital	38,436	37,472	34,768	30,349	28,037	37,791
Book Value Per Share	6167.71	5919.73	5609.93	5310.44	5103.62	5231.12
Tangible Book Value	52,492	50,323	47,673	44,738	43,157	44,255
Tangible Book Value Per Share	6096.21	5844.37	5536.52	5195.72	5012.04	5139.55
Land	7,011	7,011	7,061	5,464	5,464	4,115
Buildings	10,084	3,759	6,533	6,489	6,471	4,101
Machinery	9,848	1,931	9,342	9,255	9,222	9,140
Construction In Progress	-	595.13	41.65	1,620	1,007	1,935

Source: S&P Global Market Intelligence. Standard template. Financial Sources.